<DOC>
	<DOCNO>NCT00068211</DOCNO>
	<brief_summary>This Phase II , non-randomized , open label study ILX651 patient inoperable locally advanced metastatic melanoma . Approximately 60 patient enrol study expect last 18 month . All patient treat ILX651 administer IV daily 5 consecutive day every 21 day . The primary objective study determine overall response rate patient treat ILX651 . The secondary objective determine progression free survival 18 week , duration response , time tumor progression , survival , safety/tolerability ILX651 evaluate pharmacokinetic profile .</brief_summary>
	<brief_title>Study ILX651 Patients With Inoperable Locally Advanced Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically cytologically confirm inoperable locally advanced metastatic malignant melanoma . Measurable disease . Measurable lesion outside field radiation . Where measurable lesion within previously irradiate field , must objective evidence progression lesion prior patient enrollment . Male female patient great equal 18 year age . ECOG performance status 0 1 . Must adequate organ immune system function indicate follow laboratory value , obtain less equal 2 week prior registration : A . Absolute neutrophil count ( ANC ) great equal 1.5 x 1,000,000,000 . B.Hemoglobin great equal 9.0 g/Dl . C. Platelet count great equal 100 x 1,000,000,000/L . E. Serum creatinine calculate creatinine clearance less equal 1.5 mg/dL great equal 60 mL/min . F. Serum total bilirubin less equal 2.0 mg/dL . G. AST ALT less equal 3 time upper limit normal ( ULN ) OR le 5 time ULN secondary liver metastasis . H. Alkaline phosphatase less equal 5 time ULN ( unless bone metastasis present absence liver metastasis ) . Anticancer therapy , major surgery , irradiation must complete least 4 week enrollment study . Patient must recover acute side effect incur result previous therapy . Female patient childbearing potential must negative pregnancy test within 7 day study enrollment . Men woman reproductive potential must use effective contraceptive method enrol study . Signed informed consent ( include HIPAA authorization ) . Patients uncontrolled congestive heart failure angina , patient history myocardial infarction within 2 month enrollment , patient cardiac functional capacity Class III IV define New York Heart Association Classification . Previously treat systemic chemotherapy . Prior radiotherapy site measurable disease . Known hypersensitivity study drug analog . Active ocular melanoma . Patients primary diagnosis ocular melanoma exclude provided primary ocular melanoma longer present recurrence distal . Use investigational agent within previous 30 day . Known , active infection , know HIV positive presence AIDS relate illness . Active secondary malignancy . Presence symptomatic active brain metastasis , include leptomeningeal involvement . Prior evidence brain metastasis permit patient clinical complete remission least 1 month therapy . Uncontrolled hypertension . Patients hypertension must blood pressure control antihypertensive medication assess investigator . Patients prior radiation therapy great 25 % bone marrow ( eg , whole pelvic irradiation allow ) . Any significant concurrent disease illness , psychiatric disorder alcohol chemical abuse would , opinion investigator , compromise patient safety compliance , interfere interpretation study result . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Inoperable Locally Advanced Melanoma</keyword>
</DOC>